Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesAmortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in CashDepreciation & Amortization (CF)Exchange Rate EffectFree Cash FlowNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Northwest Biotherapeutics (NWBO) Amortizatization of Intangibles: 2010-2025

Historic Amortizatization of Intangibles for Northwest Biotherapeutics (NWBO) over the last 11 years, with Sep 2025 value amounting to $70,000.

  • Northwest Biotherapeutics' Amortizatization of Intangibles fell 9.09% to $70,000 in Q3 2025 from the same period last year, while for Sep 2025 it was $277,000, marking a year-over-year decrease of 10.36%. This contributed to the annual value of $650,000 for FY2020, which is 301.86% up from last year.
  • Per Northwest Biotherapeutics' latest filing, its Amortizatization of Intangibles stood at $70,000 for Q3 2025, which was up 6.06% from $66,000 recorded in Q2 2025.
  • In the past 5 years, Northwest Biotherapeutics' Amortizatization of Intangibles registered a high of $93,000 during Q1 2021, and its lowest value of $56,000 during Q2 2021.
  • For the 3-year period, Northwest Biotherapeutics' Amortizatization of Intangibles averaged around $71,889, with its median value being $71,000 (2023).
  • Over the last 5 years, Northwest Biotherapeutics' Amortizatization of Intangibles had its largest YoY gain of 16.25% in 2021, and its largest YoY loss of 33.72% in 2021.
  • Northwest Biotherapeutics' Amortizatization of Intangibles (Quarterly) stood at $57,000 in 2021, then rose by 10.53% to $63,000 in 2022, then climbed by 15.87% to $73,000 in 2023, then rose by 5.48% to $77,000 in 2024, then dropped by 9.09% to $70,000 in 2025.
  • Its Amortizatization of Intangibles stands at $70,000 for Q3 2025, versus $66,000 for Q2 2025 and $64,000 for Q1 2025.